Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Depression

  Free Subscription


Articles published in Am J Psychiatry

Retrieve available abstracts of 122 articles:
HTML format



Single Articles


    April 2024
  1. KAVIRAJAN H
    Neglect of Adverse Effects in Treatment Guidelines for Depression.
    Am J Psychiatry. 2024;181:342-345.
    PubMed    


    March 2024
  2. STEFFENS DC
    Late-Life Depression, Antidepressant Treatment, and Cognition: The Short Haul and the Long Haul.
    Am J Psychiatry. 2024;181:183-185.
    PubMed    


  3. PHILLIPS ML
    Multimodal Predictors of Treatment Response in Major Depressive Disorder: Advancing Personalized Medicine in Psychiatry.
    Am J Psychiatry. 2024;181:180-182.
    PubMed    


  4. POIROT MG, Ruhe HG, Mutsaerts HMM, Maximov II, et al
    Treatment Response Prediction in Major Depressive Disorder Using Multimodal MRI and Clinical Data: Secondary Analysis of a Randomized Clinical Trial.
    Am J Psychiatry. 2024;181:223-233.
    PubMed     Abstract available


    February 2024
  5. AINSWORTH NJ, Marawi T, Maslej MM, Blumberger DM, et al
    Cognitive Outcomes After Antidepressant Pharmacotherapy for Late-Life Depression: A Systematic Review and Meta-Analysis.
    Am J Psychiatry. 2024 Feb 7:appiajp20230392. doi: 10.1176/appi.ajp.20230392.
    PubMed     Abstract available


    January 2024
  6. KALIN NH
    Improving Clinical Outcomes and Informing New Interventions.
    Am J Psychiatry. 2024;181:1-3.
    PubMed    


  7. WALASZEK A
    Optimizing the Treatment of Late-Life Depression.
    Am J Psychiatry. 2024;181:7-10.
    PubMed    


  8. RUBINOW DR
    Suicide and the Menstrual Cycle.
    Am J Psychiatry. 2024;181:11-13.
    PubMed    


  9. BATAIL JV, Feyder MT, Bentzley BS, Williams NR, et al
    An Avenue for Optimization of Theta Burst Stimulation Protocols? Comments on the FOUR-D Randomized Noninferiority Clinical Trial.
    Am J Psychiatry. 2024;181:68-70.
    PubMed    


    December 2023
  10. KALIN NH
    Adversity and Resilience, Postpartum Depression, Suicide, and Racial/Ethnic Disparities.
    Am J Psychiatry. 2023;180:859-861.
    PubMed    


  11. ADAMS JAM, Chandra P, Mehta D
    The First Large GWAS Meta-Analysis for Postpartum Depression.
    Am J Psychiatry. 2023;180:862-864.
    PubMed    


  12. STOWE ZN
    Perinatal Mental Health: Advances and Opportunities.
    Am J Psychiatry. 2023;180:874-877.
    PubMed    


    October 2023
  13. GUINTIVANO J, Byrne EM, Kiewa J, Yao S, et al
    Meta-Analyses of Genome-Wide Association Studies for Postpartum Depression.
    Am J Psychiatry. 2023 Oct 18:appiajp20230053. doi: 10.1176/appi.ajp.20230053.
    PubMed     Abstract available


  14. ISHTIAK-AHMED K, Musliner KL, Christensen KS, Mortensen EL, et al
    Real-World Evidence on Clinical Outcomes of Commonly Used Antidepressants in Older Adults Initiating Antidepressants for Depression: A Nationwide Cohort Study in Denmark.
    Am J Psychiatry. 2023 Oct 18:appiajp20230356. doi: 10.1176/appi.ajp.20230356.
    PubMed     Abstract available


  15. SHACKMAN AJ, Gee DG
    Maternal Perinatal Stress Associated With Offspring Negative Emotionality, But the Underlying Mechanisms Remain Elusive.
    Am J Psychiatry. 2023;180:708-711.
    PubMed    


  16. KALIN NH
    Stress, Heritability, and Genetic Factors Influencing Depression, PTSD, and Suicidal Behavior.
    Am J Psychiatry. 2023;180:699-702.
    PubMed    


  17. LYNALL ME, McIntosh AM
    The Heterogeneity of Depression.
    Am J Psychiatry. 2023;180:703-704.
    PubMed    


  18. NGUYEN TD, Kowalec K, Pasman J, Larsson H, et al
    Genetic Contribution to the Heterogeneity of Major Depressive Disorder: Evidence From a Sibling-Based Design Using Swedish National Registers.
    Am J Psychiatry. 2023;180:714-722.
    PubMed     Abstract available


  19. FARHAT LC, Blakey R, Davey Smith G, Fujita A, et al
    Networks of Neurodevelopmental Traits, Socioenvironmental Factors, Emotional Dysregulation in Childhood, and Depressive Symptoms Across Development in Two U.K. Cohorts.
    Am J Psychiatry. 2023;180:755-765.
    PubMed     Abstract available


  20. CHATZINAKOS C, Pernia CD, Morrison FG, Iatrou A, et al
    Single-Nucleus Transcriptome Profiling of Dorsolateral Prefrontal Cortex: Mechanistic Roles for Neuronal Gene Expression, Including the 17q21.31 Locus, in PTSD Stress Response.
    Am J Psychiatry. 2023;180:739-754.
    PubMed     Abstract available


  21. DOCHERTY AR, Mullins N, Ashley-Koch AE, Qin X, et al
    GWAS Meta-Analysis of Suicide Attempt: Identification of 12 Genome-Wide Significant Loci and Implication of Genetic Risks for Specific Health Factors.
    Am J Psychiatry. 2023;180:723-738.
    PubMed     Abstract available


    September 2023
  22. PINE DS
    Zuranolone Treatment for Depression: Steady Progress in Mechanism-Focused Therapeutics?
    Am J Psychiatry. 2023;180:631-633.
    PubMed    


  23. KALIN NH
    Seeking New Solutions Addressing Structural Racism, Childhood Trauma, Suicidal Behaviors Across Sexual Orientations, and Postpartum Depression.
    Am J Psychiatry. 2023;180:625-628.
    PubMed    


  24. CLAYTON AH, Lasser R, Parikh SV, Iosifescu DV, et al
    Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial.
    Am J Psychiatry. 2023;180:676-684.
    PubMed     Abstract available


    July 2023
  25. DELIGIANNIDIS KM, Meltzer-Brody S, Maximos B, Peeper EQ, et al
    Zuranolone for the Treatment of Postpartum Depression.
    Am J Psychiatry. 2023 Jul 26:appiajp20220785. doi: 10.1176/appi.ajp.20220785.
    PubMed     Abstract available


  26. JESTER DJ, Kohn JN, Tibirica L, Thomas ML, et al
    Differences in Social Determinants of Health Underlie Racial/Ethnic Disparities in Psychological Health and Well-Being: Study of 11,143 Older Adults.
    Am J Psychiatry. 2023;180:483-494.
    PubMed     Abstract available


    April 2023
  27. BIERNACKA JM
    Do Polygenic Scores Inform Psychiatric Disease Risk After Considering Family History?
    Am J Psychiatry. 2023;180:256-258.
    PubMed    


    March 2023
  28. ELBAU IG, Lynch CJ, Downar J, Vila-Rodriguez F, et al
    Functional Connectivity Mapping for rTMS Target Selection in Depression.
    Am J Psychiatry. 2023;180:230-240.
    PubMed     Abstract available


  29. THASE ME
    A New Option for Depressed Patients Who Do Not Respond to Antidepressant Medications.
    Am J Psychiatry. 2023;180:188-189.
    PubMed    


  30. KALIN NH
    Insights and Advances Into Treatments for Major Depression.
    Am J Psychiatry. 2023;180:173-176.
    PubMed    


  31. JHA MK, Mathew SJ
    Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape.
    Am J Psychiatry. 2023;180:190-199.
    PubMed     Abstract available


  32. NUNES EV
    Alcohol and the Etiology of Depression.
    Am J Psychiatry. 2023;180:179-181.
    PubMed    


  33. SACHS GS, Yeung PP, Rekeda L, Khan A, et al
    Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.
    Am J Psychiatry. 2023;180:241-251.
    PubMed     Abstract available


  34. DUNLOP BW, Cha J, Choi KS, Rajendra JK, et al
    Shared and Unique Changes in Brain Connectivity Among Depressed Patients After Remission With Pharmacotherapy Versus Psychotherapy.
    Am J Psychiatry. 2023;180:218-229.
    PubMed     Abstract available


  35. HASSERIS S, Albinana C, Vilhjalmsson BJ, Mortensen PB, et al
    Polygenic Risk and Episode Polarity Among Individuals With Bipolar Disorder.
    Am J Psychiatry. 2023;180:200-208.
    PubMed     Abstract available


    February 2023
  36. BELSKY DW, Domingue BW
    Progress and Challenges in GxE Research on Depression.
    Am J Psychiatry. 2023;180:111-113.
    PubMed    


    January 2023
  37. VISONTAY R, Mewton L, Slade T, Aris IM, et al
    Moderate Alcohol Consumption and Depression: A Marginal Structural Model Approach Promoting Causal Inference.
    Am J Psychiatry. 2023 Jan 18:appiajp22010043. doi: 10.1176/appi.ajp.22010043.
    PubMed     Abstract available


  38. CLEARY JL, Fang Y, Zahodne LB, Bohnert ASB, et al
    Polygenic Risk and Social Support in Predicting Depression Under Stress.
    Am J Psychiatry. 2023 Jan 11:appiajp21111100. doi: 10.1176/appi.ajp.21111100.
    PubMed     Abstract available


    December 2022
  39. BARBER G, Nemeroff CB, Siegel S
    A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability.
    Am J Psychiatry. 2022;179:892-896.
    PubMed    


  40. SCHATZBERG AF
    An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression.
    Am J Psychiatry. 2022;179:890-891.
    PubMed    


  41. PRICE RB, Spotts C, Panny B, Griffo A, et al
    A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial.
    Am J Psychiatry. 2022;179:959-968.
    PubMed     Abstract available


    November 2022
  42. JESPERSEN A, Yilmaz Z, Vilhjalmsson BJ
    Harnessing the Power of Population Cohorts to Study the Relationship Between Endocrine-Metabolic Disorders and Depression.
    Am J Psychiatry. 2022;179:788-790.
    PubMed    


  43. URSANO RJ, Stein MB
    From Soldier's Heart to Shared Genetic Risk: PTSD and Cardiovascular Disease.
    Am J Psychiatry. 2022;179:785-787.
    PubMed    


  44. SELIGOWSKI AV, Misganaw B, Duffy LA, Ressler KJ, et al
    Leveraging Large-Scale Genetics of PTSD and Cardiovascular Disease to Demonstrate Robust Shared Risk and Improve Risk Prediction Accuracy.
    Am J Psychiatry. 2022;179:814-823.
    PubMed     Abstract available


  45. SIGSTROM R, Kowalec K, Jonsson L, Clements CC, et al
    Association Between Polygenic Risk Scores and Outcome of ECT.
    Am J Psychiatry. 2022;179:844-852.
    PubMed     Abstract available


    September 2022
  46. LEONE M, Kuja-Halkola R, Leval A, Butwicka A, et al
    Genetic and Environmental Contribution to the Co-Occurrence of Endocrine-Metabolic Disorders and Depression: A Nationwide Swedish Study of Siblings.
    Am J Psychiatry. 2022 Sep 21:appiajp21090954. doi: 10.1176/appi.ajp.21090954.
    PubMed     Abstract available


  47. MARKOWITZ JC, Wright JH, Peeters F, Thase ME, et al
    Psychotherapy's Role for Treatment-Resistant Depression: Reply to Bartova et al.
    Am J Psychiatry. 2022;179:688.
    PubMed    


  48. RICE F
    The Intergenerational Transmission of Anxiety Disorders and Major Depression.
    Am J Psychiatry. 2022;179:596-598.
    PubMed    


  49. DURGAM S, Chen R, Calabrese JR, Sachs GS, et al
    Treatments for Depression in Bipolar II Disorder.
    Am J Psychiatry. 2022;179:688-690.
    PubMed    


  50. BARTOVA L, Fugger G, Dold M, Kautzky A, et al
    Psychotherapy's Role for Treatment-Resistant Depression?
    Am J Psychiatry. 2022;179:687.
    PubMed    


  51. OSTACHER M
    Treatments for Depression in Bipolar II Disorder: Reply to Durgam et al.
    Am J Psychiatry. 2022;179:690.
    PubMed    


  52. KENDLER KS, Abrahamsson L, Ohlsson H, Sundquist J, et al
    An Extended Swedish Adoption Study of Anxiety Disorder and Its Cross-Generational Familial Relationship With Major Depression.
    Am J Psychiatry. 2022;179:640-649.
    PubMed     Abstract available


  53. JAFFE AE, Tao R, Page SC, Maynard KR, et al
    Decoding Shared Versus Divergent Transcriptomic Signatures Across Cortico-Amygdala Circuitry in PTSD and Depressive Disorders.
    Am J Psychiatry. 2022;179:673-686.
    PubMed     Abstract available


    July 2022
  54. HARVEY PD
    Digital Therapeutics to Enhance Cognition in Major Depression: How Can We Make the Cognitive Gains Translate Into Functional Improvements?
    Am J Psychiatry. 2022;179:445-447.
    PubMed    


  55. FERRARELLI F
    Is Neuroplasticity Key to Treatment Response in Depression? Maybe So.
    Am J Psychiatry. 2022;179:451-453.
    PubMed    


  56. PIZZAGALLI DA
    Toward a Better Understanding of the Mechanisms and Pathophysiology of Anhedonia: Are We Ready for Translation?
    Am J Psychiatry. 2022;179:458-469.
    PubMed     Abstract available


  57. TAMM S, Harmer CJ, Schiel J, Holub F, et al
    No Association Between Amygdala Responses to Negative Faces and Depressive Symptoms: Cross-Sectional Data from 28,638 Individuals in the UK Biobank Cohort.
    Am J Psychiatry. 2022;179:509-513.
    PubMed    


  58. KALIN NH
    Neuroscientific Advances Supporting New Treatments for Major Depression.
    Am J Psychiatry. 2022;179:441-444.
    PubMed    


  59. GROGANS SE, Fox AS, Shackman AJ
    The Amygdala and Depression: A Sober Reconsideration.
    Am J Psychiatry. 2022;179:454-457.
    PubMed    


  60. TABUTEAU H, Jones A, Anderson A, Jacobson M, et al
    Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial.
    Am J Psychiatry. 2022;179:490-499.
    PubMed     Abstract available


    June 2022
  61. HANKERSON SH, Moise N, Wilson D, Waller BY, et al
    The Intergenerational Impact of Structural Racism and Cumulative Trauma on Depression.
    Am J Psychiatry. 2022;179:434-440.
    PubMed     Abstract available


    May 2022
  62. GE R, Humaira A, Gregory E, Alamian G, et al
    Predictive Value of Acute Neuroplastic Response to rTMS in Treatment Outcome in Depression: A Concurrent TMS-fMRI Trial.
    Am J Psychiatry. 2022 May 18:appiajp21050541. doi: 10.1176/appi.ajp.21050541.
    PubMed     Abstract available


  63. PAN PM, Sato JR, Paillere Martinot ML, Martinot JL, et al
    Longitudinal Trajectory of the Link Between Ventral Striatum and Depression in Adolescence.
    Am J Psychiatry. 2022 May 18:appiajp20081180. doi: 10.1176/appi.ajp.20081180.
    PubMed     Abstract available


    April 2022
  64. KEEFE RSE, Canadas E, Farlow D, Etkin A, et al
    Digital Intervention for Cognitive Deficits in Major Depression: A Randomized Controlled Trial to Assess Efficacy and Safety in Adults.
    Am J Psychiatry. 2022 Apr 12:appiajp21020125. doi: 10.1176/appi.ajp.21020125.
    PubMed     Abstract available


    February 2022
  65. MARKOWITZ JC, Wright JH, Peeters F, Thase ME, et al
    The Neglected Role of Psychotherapy for Treatment-Resistant Depression.
    Am J Psychiatry. 2022;179:90-93.
    PubMed    


  66. WEISSMAN CR, Daskalakis ZJ
    Accelerated Intermittent Theta Burst Stimulation: Expediting and Enhancing Treatment Outcomes in Treatment-Resistant Depression.
    Am J Psychiatry. 2022;179:85-87.
    PubMed    


  67. NEMEROFF CB
    Back to the Future: Esmethadone, the (Maybe) Nonopiate Opiate, and Depression.
    Am J Psychiatry. 2022;179:83-84.
    PubMed    


  68. FAVA M, Stahl S, Pani L, De Martin S, et al
    REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial.
    Am J Psychiatry. 2022;179:122-131.
    PubMed     Abstract available


  69. COLE EJ, Phillips AL, Bentzley BS, Stimpson KH, et al
    Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial.
    Am J Psychiatry. 2022;179:132-141.
    PubMed     Abstract available


    January 2022
  70. KVARTA M, Ma Y, Hong LE
    Comment on "Elevated C-Reactive Protein in Patients With Depression, Independent of Genetic, Health, and Psychosocial Factors: Results From the UK Biobank".
    Am J Psychiatry. 2022;179:73.
    PubMed    


    December 2021
  71. MCINTYRE RS
    Ketamine and Esketamine for Treatment-Resistant Depression: Response to Reus, Mattes, and Schatzberg.
    Am J Psychiatry. 2021;178:1130-1132.
    PubMed    


  72. PARIANTE CM
    Increased Inflammation in Depression: A Little in All, or a Lot in a Few?
    Am J Psychiatry. 2021;178:1077-1079.
    PubMed    


  73. KALIN NH
    New Insights Into Major Depression and the Treatment of Bipolar Depression.
    Am J Psychiatry. 2021;178:1071-1074.
    PubMed    


  74. CONROY SK, Holtzheimer PE
    Neuromodulation Strategies for the Treatment of Depression.
    Am J Psychiatry. 2021;178:1082-1088.
    PubMed     Abstract available


  75. OSTACHER MJ
    Slowly Working Toward More Treatments for Depression in Bipolar II Disorder.
    Am J Psychiatry. 2021;178:1075-1076.
    PubMed    


  76. SCHATZBERG AF
    Mechanisms of Action of Ketamine and Esketamine.
    Am J Psychiatry. 2021;178:1130.
    PubMed    


  77. REUS VI
    Recommendations for the Usage of Ketamine and Esketamine.
    Am J Psychiatry. 2021;178:1129.
    PubMed    


  78. ZHUKOVSKY P, Anderson JAE, Coughlan G, Mulsant BH, et al
    Coordinate-Based Network Mapping of Brain Structure in Major Depressive Disorder in Younger and Older Adults: A Systematic Review and Meta-Analysis.
    Am J Psychiatry. 2021;178:1119-1128.
    PubMed     Abstract available


  79. CALABRESE JR, Durgam S, Satlin A, Vanover KE, et al
    Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial.
    Am J Psychiatry. 2021;178:1098-1106.
    PubMed     Abstract available


    November 2021
  80. KEDING TJ, Heyn SA, Russell JD, Zhu X, et al
    Differential Patterns of Delayed Emotion Circuit Maturation in Abused Girls With and Without Internalizing Psychopathology.
    Am J Psychiatry. 2021;178:1026-1036.
    PubMed     Abstract available


    October 2021
  81. FRANK P, Jokela M, Batty GD, Cadar D, et al
    Association Between Systemic Inflammation and Individual Symptoms of Depression: A Pooled Analysis of 15 Population-Based Cohort Studies.
    Am J Psychiatry. 2021 Oct 14:appiajp202120121776.
    PubMed     Abstract available


  82. KALIN NH
    Depression and Schizophrenia: Sleep, Medical Risk Factors, Biomarkers, and Treatment.
    Am J Psychiatry. 2021;178:881-884.
    PubMed    


  83. PLANTE DT
    The Evolving Nexus of Sleep and Depression.
    Am J Psychiatry. 2021;178:896-902.
    PubMed     Abstract available


  84. MCINTYRE RS
    Surrogate Markers of Insulin Resistance in Predicting Major Depressive Disorder: Metabolism Metastasizes to the Brain.
    Am J Psychiatry. 2021;178:885-887.
    PubMed    


  85. WATSON KT, Simard JF, Henderson VW, Nutkiewicz L, et al
    Incident Major Depressive Disorder Predicted by Three Measures of Insulin Resistance: A Dutch Cohort Study.
    Am J Psychiatry. 2021;178:914-920.
    PubMed     Abstract available


    July 2021
  86. ROXAS N, Ahuja C, Isom J, Wilkinson ST, et al
    A Potential Case of Acute Ketamine Withdrawal: Clinical Implications for the Treatment of Refractory Depression.
    Am J Psychiatry. 2021;178:588-591.
    PubMed    


    June 2021
  87. PENNINX BWJH
    Using the Power of a Giant Wisely: Confirming Inflammation in Depression.
    Am J Psychiatry. 2021;178:480-482.
    PubMed    


  88. KALIN NH
    COVID-19 and Stress-Related Disorders.
    Am J Psychiatry. 2021;178:471-474.
    PubMed    


  89. RUBINOW DR, Lasser R, Kanes SJ
    Comment on "Understanding the Clinical Effects and Mechanisms of Action of Neurosteroids".
    Am J Psychiatry. 2021;178:572-573.
    PubMed    


    May 2021
  90. PITHAROULI MC, Hagenaars SP, Glanville KP, Coleman JRI, et al
    Elevated C-Reactive Protein in Patients With Depression, Independent of Genetic, Health, and Psychosocial Factors: Results From the UK Biobank.
    Am J Psychiatry. 2021 May 14:appiajp202020060947.
    PubMed     Abstract available


  91. MAIXNER DF, Weiner R, Reti IM, Hermida AP, et al
    Electroconvulsive Therapy Is an Essential Procedure.
    Am J Psychiatry. 2021;178:381-382.
    PubMed    


  92. SCHATZBERG AF
    Can Target Engagement Studies Miss Their Targets and Mislead Drug Development?
    Am J Psychiatry. 2021;178:372-374.
    PubMed    


  93. FERRARELLI F, Phillips ML
    Examining and Modulating Neural Circuits in Psychiatric Disorders With Transcranial Magnetic Stimulation and Electroencephalography: Present Practices and Future Developments.
    Am J Psychiatry. 2021;178:400-413.
    PubMed     Abstract available


    April 2021
  94. KALIN NH
    Anxiety, Depression, and Suicide in Youth.
    Am J Psychiatry. 2021;178:275-279.
    PubMed    


  95. PARIKH T, Walkup JT
    The Future of Ketamine in the Treatment of Teen Depression.
    Am J Psychiatry. 2021;178:288-289.
    PubMed    


  96. NEMEROFF CB
    The Trifecta of Misery and Disease Vulnerability: Poverty, Childhood Maltreatment, and Inflammation.
    Am J Psychiatry. 2021;178:282-284.
    PubMed    


  97. BOELEN PA, Lenferink LIM, Spuij M
    CBT for Prolonged Grief in Children and Adolescents: A Randomized Clinical Trial.
    Am J Psychiatry. 2021;178:294-304.
    PubMed     Abstract available


  98. SEQUEIRA SL, Silk JS, Ladouceur CD, Hanson JL, et al
    Association of Neural Reward Circuitry Function With Response to Psychotherapy in Youths With Anxiety Disorders.
    Am J Psychiatry. 2021;178:343-351.
    PubMed     Abstract available


  99. BIERMAN KL, Heinrichs BS, Welsh JA, Nix RL, et al
    Reducing Adolescent Psychopathology in Socioeconomically Disadvantaged Children With a Preschool Intervention: A Randomized Controlled Trial.
    Am J Psychiatry. 2021;178:305-312.
    PubMed     Abstract available


    March 2021
  100. MCINTYRE RS, Rosenblat JD, Nemeroff CB, Sanacora G, et al
    Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
    Am J Psychiatry. 2021 Mar 17:appiajp202020081251.
    PubMed     Abstract available


  101. DWYER JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, et al
    Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
    Am J Psychiatry. 2021 Mar 3:appiajp202020010018.
    PubMed     Abstract available


  102. COSTI S, Morris LS, Kirkwood KA, Hoch M, et al
    Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial.
    Am J Psychiatry. 2021 Mar 3:appiajp202020050653.
    PubMed     Abstract available


  103. RUBINOW DR
    One Small Step for PMDD, One Large Step for Affective Disorders.
    Am J Psychiatry. 2021;178:215-217.
    PubMed    


  104. COMASCO E, Kopp Kallner H, Bixo M, Hirschberg AL, et al
    Ulipristal Acetate for Treatment of Premenstrual Dysphoric Disorder: A Proof-of-Concept Randomized Controlled Trial.
    Am J Psychiatry. 2021;178:256-265.
    PubMed     Abstract available


  105. KLEINMAN RA, Schatzberg AF
    Understanding the Clinical Effects and Mechanisms of Action of Neurosteroids.
    Am J Psychiatry. 2021;178:221-223.
    PubMed    


    February 2021
  106. SUMMERS RF, Gorrindo T, Hwang S, Aggarwal R, et al
    Psychiatrist Burnout: Response to Schonfeld and Bianchi.
    Am J Psychiatry. 2021;178:204-205.
    PubMed    


  107. SCHONFELD IS, Bianchi R
    Psychiatrist Burnout.
    Am J Psychiatry. 2021;178:204.
    PubMed    


  108. FEDER A, Costi S, Rutter SB, Collins AB, et al
    A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.
    Am J Psychiatry. 2021;178:193-202.
    PubMed     Abstract available


    January 2021
  109. SHMULEWITZ D, Aharonovich E, Witkiewitz K, Anton RF, et al
    The World Health Organization Risk Drinking Levels Measure of Alcohol Consumption: Prevalence and Health Correlates in Nationally Representative Surveys of U.S. Adults, 2001-2002 and 2012-2013.
    Am J Psychiatry. 2021 Jan 21:appiajp202020050610.
    PubMed     Abstract available


    November 2020
  110. SINHA R, Wemm S, Fogelman N, Milivojevic V, et al
    Moderation of Prazosin's Efficacy by Alcohol Withdrawal Symptoms.
    Am J Psychiatry. 2020 Nov 19:appiajp202020050609.
    PubMed     Abstract available


    October 2020
  111. COUGHLIN LN, Pfeiffer P, Ganoczy D, Lin LA, et al
    Quality of Outpatient Depression Treatment in Patients With Comorbid Substance Use Disorder.
    Am J Psychiatry. 2020 Oct 29:appiajp202020040454.
    PubMed     Abstract available


  112. MATHEW SJ
    Is Testosterone an Effective Hormonal Therapy for Women With Antidepressant-Resistant Major Depression?
    Am J Psychiatry. 2020;177:891-894.
    PubMed    


  113. KALIN NH
    Insights Into Suicide and Depression.
    Am J Psychiatry. 2020;177:877-880.
    PubMed    


  114. HOLMANS PA
    Using Genetics to Increase Specificity of Outcome Prediction in Psychiatric Disorders: Prospects for Progression.
    Am J Psychiatry. 2020;177:884-887.
    PubMed    


  115. FIRTH J, Wootton RE, Carvalho AF
    Toward Preventive Psychiatry: The Role of Advanced Epidemiological Methods.
    Am J Psychiatry. 2020;177:888-890.
    PubMed    


  116. SUMMERS RF
    The Elephant in the Room: What Burnout Is and What It Is Not.
    Am J Psychiatry. 2020;177:898-899.
    PubMed    


  117. MEDINA-RODRIGUEZ EM, Madorma D, O'Connor G, Mason BL, et al
    Identification of a Signaling Mechanism by Which the Microbiome Regulates Th17 Cell-Mediated Depressive-Like Behaviors in Mice.
    Am J Psychiatry. 2020;177:974-990.
    PubMed     Abstract available


  118. DICHTEL LE, Carpenter LL, Nyer M, Mischoulon D, et al
    Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study.
    Am J Psychiatry. 2020;177:965-973.
    PubMed     Abstract available


    August 2020
  119. MUELLER SC
    Mental Health Treatment Utilization in Transgender Persons: What We Know and What We Don't Know.
    Am J Psychiatry. 2020;177:657-659.
    PubMed    


  120. CARPENTER LL, Philip NS
    The Future Is Now? Rapid Advances by Brain Stimulation Innovation.
    Am J Psychiatry. 2020;177:654-656.
    PubMed    


  121. THASE ME
    Charting Sea Changes in Outpatient Pharmacotherapy of Bipolar Disorder.
    Am J Psychiatry. 2020;177:651-653.
    PubMed    


  122. DWYER JB, Aftab A, Radhakrishnan R, Widge A, et al
    Hormonal Treatments for Major Depressive Disorder: State of the Art.
    Am J Psychiatry. 2020;177:686-705.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Depression is free of charge.